Melinta Therapeutics Announces One-for-Five Reverse Stock Split
21 févr. 2019 13h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Provides Corporate Updates
04 févr. 2019 08h00 HE
|
Melinta Therapeutics
~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New...
John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics
19 déc. 2018 08h31 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million
19 déc. 2018 08h30 HE
|
Melinta Therapeutics
~ Credit Facility has Option to be Converted into Preferred Shares ~ ~ Adjourns Special Meeting of Stockholders Scheduled for December 20, 2018 ~ ~ Reaffirms Product Sales and Cost Savings...
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
27 nov. 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Reports Third Quarter 2018 Financial Results
07 nov. 2018 07h00 HE
|
Melinta Therapeutics
New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin® for Injection in 68...
UPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors
31 oct. 2018 17h16 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
29 oct. 2018 08h00 HE
|
Melinta Therapeutics
– Met primary endpoint of Early Clinical Response at 96 hours after the first dose – – Supplemental NDA expected to be filed with FDA in 1H 2019 – – Baxdela currently FDA approved for treatment of...
Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
26 oct. 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer
22 oct. 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...